lifestyle.californiaconsumerbanking.com

Author: SEED Therapeutics

SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting

May 18, 2026
SEED Therapeutics Reports Tumor Eradication in a Neuroblastoma In Vivo Model with Clinical-Stage RBM39 Molecular Glue Degrader ST-01156

May 7, 2026
SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026

May 4, 2026